MBI - Pharma manufacturing consent decrees

Start Date: 2005
Financial penalties: none
End Date: still pending

This case mixes marketing and manufacturing violations.

The regulator cited the company for nonconformance with manufacturing regulations at a California facility that made over-the-counter eye drops. The FDA found also that two of the company's eye drop brands were unapproved, and that products had inadequate warning labels.

MBI - Pharma manufacturing consent decrees
Read more on